Jeffrey Lee, MD, MPH and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi discuss “Impact of a Scalable Training Program on the Quality of Colonoscopy Performance and Risk of Post-Colonoscopy Colorectal Cancer,” by Corley DA, Jensen CD, Lee JK, et al. Gastrointest Endosc [2023; In Press].

Philip Okafor, MD, MPH and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi discuss “Frequency of Use and Outcomes in Individuals Older than 75 Years,” by El Halabi J, Burke CA, Hariri E, et al. JAMA Internal Medicine [2023; 183: 513-19].

Jacqueline Gaulin and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi discuss “Response-Guided Therapy with Cefotaxime, Ceftriaxone, or Ciprofloxacin for Spontaneous Bacterial Peritonitis: A Validation Study of 2021 AASLD Practice Guideline for SBP,” by Yim HJ, Kim TH, Suh SJ, et al. Am J Gastroenterol [2023; 118: 654-63].

Jacqueline Gaulin and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi discuss “AGA-ACG Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation,” by Chang L, Chey WD, Imdad A, et al. Am J Gastroenterol [2023; 118: 936-54].

Shria Kumar, MD, MSCE and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi discuss “Effect of Disposable Elevator Cap Duodenoscopes on Persistent Microbial Contamination and Technical Performance of Endoscopic Retrograde Cholangiopancreatography: The ICECAP Randomized Clinical Trial,” by Forbes N, Elmunzer BJ, Allain T, et al. JAMA Intern Med [2023;183(3):191-200].

Jennifer Kolb, MD, MS and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi discuss “Comparison of Over-the-Scope Clips to Standard Endoscopic Treatment as the Initial Treatment in Patients With Bleeding From a Nonvariceal Upper Gastrointestinal Cause: A Randomized Controlled Trial,” by Lau JYW, Li R, Tan C et al. Ann Intern Med [2023 Apr;176(4):455-462].

Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi discusses “Effect of Prophylactic Antibiotics on Mortality in Severe Alcohol-Related Hepatitis,” by Louvet A, Labreuche J, Dao T, et al. [JAMA 2023; 329 (18): 1558-66].

Bharati Kochar, MD, MS and Editor-in-Chief Philip Schoenfeld, MD, MSEd discuss “Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn’s disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial,” by Sands BE, Irving PM, Hoops T, et al. Lancet [2022;399(10342):2200-2211].

Jessica Allegretti, MD, MPH and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi discuss “Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis,” by Sands BE, Peyrin-Biroulet L, Loftus EV Jr, Danese S, Colombel JF, Toruner M, Jonaitis L, Abhyankar B, Chen J, Rogers R, Lirio RA, Bornstein JD, Schreiber S. N Engl J Med [2019 Sep 26;381(13):1215-1226].

Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi discussesEditor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi discusses “Randomized Placebo-Controlled Phase 3 Trial of Vibrating Capsule for Chronic Constipation,” by Rao S, Quigley EMM, Chey WD, et al. Gastroenterology [2023].